Wenshu Leng

Clinical Benefit With PARP Inhibitor for Pathogenic Germline FANCA-Mutated Relapsed Epithelial Ovarian Cancer: A Case Report

Shiqing Chen, H. Yi, Zhengqing Yan, 2021, Frontiers in Oncology.